Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY... ( RIDGEFIELD Conn. Jan. 17 /- Boehr...)

HOME >> MEDICINE >> TECHNOLOGY

Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study

Date:1/17/2008

RIDGEFIELD, Conn., Jan. 17 /PRNewswire/ -- Boehringer Ingelheim announced today that enrollment is complete for the landmark RE-LY trial to evaluate the long-term efficacy and safety of investigational oral direct thrombin inhibitor dabigatran etexilate for the prevention of stroke and systemic embolism in patients with atrial fibrillation. RE-LY (Randomized Evaluation of Long Term Anticoagulant Therapy) is the largest stroke prevention in atrial fibrillation trial conducted to date, with 18,114 patients, in 1,000 centers in 44 countries worldwide enrolled between December 2005 and December 2007. Currently, more than 10,000 patients have been treated for at least 6 months with final study results expected to be reported in early 2009.

The RE-LY trial is comparing two blinded doses of oral dabigatran etexilate with warfarin sodium (target INR 2.0-3.0) in patients with non-valvular atrial fibrillation who are at moderate-to-high risk of stroke. Currently, the standard treatment to prevent stroke in these patients is the vitamin K antagonist, warfarin. It is estimated that warfarin is currently prescribed for only half of all eligible patients.

Dr. Salim Yusuf, Professor of Epidemiology and Cardiology and head of the study coordinating center at McMaster University in Hamilton, Canada, stated that: "Patient enrollment in RE-LY has exceeded our original expectations by far."

Atrial fibrillation is the most common sustained cardiac rhythm disturbance affecting six percent of individuals over the age of 65 and 10 percent of people over the age of 80. Atrial fibrillation is a leading risk factor for stroke and, despite warfarin sodium being available as an effective treatment option, atrial fibrillation still accounts for approximately 15 percent of all strokes.

Approximately 750,000 Americans suffer a stroke each year. More than 150,000 of these strokes are fatal, making it the third leading cause of death in the United States. Approxima
'/>"/>

SOURCE Boehringer Ingelheim
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights

Post Your Comments:

(Date:6/18/2013)... BURLINGTON, Mass. , June 18, 2013 Decision ... for pharmaceutical and healthcare issues, finds that, over the past ... ( France , Germany , ... and the United Kingdom ) have been ... most of their HIV patients, primarily to reduce costs. Additionally, ...

(Date:6/18/2013)... -- Today, Wall Street Reports announced new research ... Health Management Associates Inc. (NYSE: HMA ), IDEXX ... (NASDAQ: ISIS ), and Trius Therapeutics Inc. (NASDAQ: ... - including full price targets, industry analysis and analyst ratings ... Research Report On June 7, 2013, Gilead Sciences ...

(Date:6/18/2013)... , June 18, 2013 Apama Medical, ... the development of next-generation atrial fibrillation technologies, today ... by the US Patent and Trademark Office (USPTO), ... profile electrode assemblies for use on expandable structures ... other surgical procedures. "We are grateful ...

Breaking Medicine Technology:One in Four Surveyed EU5 Physicians Has Been Required to Change a Prescription for Some or Most of Their HIV Patients in the Past Twelve Months, Primarily to Reduce Costs 2 One in Four Surveyed EU5 Physicians Has Been Required to Change a Prescription for Some or Most of Their HIV Patients in the Past Twelve Months, Primarily to Reduce Costs 3 Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 2 Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 3 Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 4 Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 5 Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 6

[0] One in Four Surveyed EU5 Physicians Has Been Required to Change a Prescription for Some or Most of Their HIV Patients in the Past Twelve Months, Primarily to Reduce Costs [0] Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics [0] Apama Medical Announces Issuance Of Patent For Low Profile Electrodes For Use On Balloons

... EVEN MORE SCIENCE SUPPORTING THE, THEORY THAT ... Mo., May 19 A primate model for ... at the,International Meeting For Autism Research (IMFAR) this ... into vaccine safety and,the immune and mitochondrial dysfunction ...

... Native Bladder by Six Months; Data Presented at May 18 Press ... ... ORLANDO, Fla. and EAST NORRITON, Pa., May 19 Tengion,Inc., a ... presented preclinical efficacy data for its,Tengion Neo-Bladder Replacement(TM) at the Annual ...

Cached Medicine Technology:UPDATE: Infant Primates Given Vaccines on U.S. Children's Immunization Schedule Develop Behavioral Symptoms of Autism 2 Preclinical Data Demonstrate Ability to Regenerate an Entire Bladder With Tengion Neo-Bladder Replacement(TM) 2

UPDATE: Infant Primates Given Vaccines on U.S. Children's Immunization Schedule Develop Behavioral Symptoms of Autism Preclinical Data Demonstrate Ability to Regenerate an Entire Bladder With Tengion Neo-Bladder Replacement(TM)

(Date:6/18/2013)... Petersburg, FL (PRWEB) June 19, 2013 ... 5 minutes a day could boost your health and ... Kathy Heshelow, founder of Sublime Beauty®. "It is called ... practiced for centuries but became a lost art. Now, ... celebrities know about Skin Brushing, and so do certain ...

(Date:6/18/2013)... June 19, 2013 An apple a ... Christina Beauregard was diagnosed with breast cancer, she chose ... new book, “I Gave Myself Cancer, I Can Take ... by Balboa Press), Beauregard explains how changing her physical, ... "Sick people have been made to feel fearful when ...

(Date:6/18/2013)... June 18, 2013 Daily Gossip Magazine has ... reviews and useful articles. , The magazine has decided ... to a new anabolic recipe every week . ... is the perfect guide for readers who are looking to ... at Daily Gossip reveals that anabolic food is almost entirely ...

(Date:6/18/2013)... 19, 2013 The Drug Delivery Partnering ... access to the drug delivery partnering deals and agreements ... , The report provides a detailed understanding and analysis ... deals. The majority of deals are discovery or development ... option right to license the license drug delivery technology. ...

(Date:6/18/2013)... Horsham, PA (PRWEB) June 18, 2013 Senior ... in Boston on June 25 to discuss—for the first time ... agencies in getting drugs through the regulatory process in a ... of drug evaluation will share respective best practices and processes ... Across the Strait panel at the DIA 2013 ...

Breaking Medicine News(10 mins):Health News:The Easiest Way to Contribute to Better Health and Well-Being Starting Today and for Under $20, Says Sublime Beauty® 2 Health News:Cancer Survivor Linda Christina Beauregard Writes New Tell-All Book About Her Alternative Treatment Method 2 Health News:Anabolic Cooking Book Review Exposes Dave Ruel’s Top 10 ‘Anabolicious’ Recipes for BodyBuilders 2 Health News:New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz 2 Health News:New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz 3 Health News:New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz 4 Health News:Renowned Regulatory Representatives From Mainland China and Taiwan to Discuss Need for Collaboration at DIA Meeting 2

[0] The Easiest Way to Contribute to Better Health and Well-Being Starting Today and for Under $20, Says Sublime Beauty®[0] Cancer Survivor Linda Christina Beauregard Writes New Tell-All Book About Her Alternative Treatment Method [0] Anabolic Cooking Book Review Exposes Dave Ruel’s Top 10 ‘Anabolicious’ Recipes for BodyBuilders [0] New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz [0] Renowned Regulatory Representatives From Mainland China and Taiwan to Discuss Need for Collaboration at DIA Meeting

... Inc. (NYSE:,CVD), a leading provider of drug development ... Merck & Co., Inc.,s Outstanding,Strategic Collaboration Award., ... 12 suppliers who,were selected from thousands of Merck ... performance; contributions towards the Key,Business Result (KBR) for ...

... GXDX ), a specialized laboratory services provider, today reported,revenues ... and $50.1 million,for the first half of 2008, as ... the respective periods in 2007. Stated revenue for the,first ... changes in,accounting estimates relating to prior periods., "Our ...

... mortality 25% in chronic kidney cases , , THURSDAY, July ... -- a routinely measured marker of bone disease -- ... receiving dialysis for chronic kidney disease, say U.S. researchers. ... patients during a three-year period. It found that patients ...

... COMMERCIAL LAUNCH OF HEARTMATE II(R) ... FOR BRIDGE-TO-TRANSPLANTATION, PLEASANTON, Calif., July 31 ... support therapies to save, support and restore failing hearts,today said that ... in the same period a year ago., Revenues for the ...

... she had hearing loss at 30, when she volunteered to ... sounds she could not hear. , Her husband Larry, ... history. Her mother, grandfather and great-grandfather had severe hearing loss ... before he reached school age. , The hearing loss ...

... 31 HealthSouth,Corporation (NYSE: HLS ) ... owned,subsidiaries, its previously announced purchase of The ... rehabilitation hospital in,Vineland, NJ, from The Mediplex/Cumberland ... South Jersey, under the outstanding,leadership of Dr. ...

Covance Recognized for Outstanding Performance by Merck & Co., Inc.Genoptix Reports Strong Financial Results for the Second Quarter and Raises Guidance for Full-Year 2008 Bone Disease Test Shows Death Risk for Dialysis Patients Thoratec Reports 44 Percent Increase in Second Quarter Revenues;Inherited form of hearing loss stems from gene mutation HealthSouth Finalizes Purchase of New Jersey Rehabilitation Hospital

Iron / TIBC (Ferrozine). Storage temp: 2 - 8 C. Linearity: 0 - 500 ug/dl. Expected values: from TIBC 250 - 400 ug/dl, from Iron 40 - 160 ug/dl. Available with Calibrator and Number of test are 100....

For the quantitative determination of iron, total iron-binding capacity in human serum....

HDL Cholesterol, liquid....

Intended for the quantitative in vitro enzymatic determination of JDL-Cholesterol in human serum or plasma. Two point reaction. Wavelength: 600 nm. Linearity: 1 to 150 mg/dL (0.03 mmol/L to 3.89 mmol...

Medicine Products:

Iron / TIBC (Ferrozine)Iron/TIBC Reagent Set HDL Cholesterol (Precipitation)HDL-Cholesterol Direct Reagent